SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "(WFRF:(Hennekens C)) srt2:(2005-2009)"

Search: (WFRF:(Hennekens C)) > (2005-2009)

  • Result 1-3 of 3
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  • Hennekens, C. H., et al. (author)
  • The CHARM program: study design leads to findings of clinical and public health importance
  • 2007
  • In: J Cardiovasc Pharmacol Ther. - : SAGE Publications. - 1074-2484. ; 12:2, s. 124-6
  • Journal article (peer-reviewed)abstract
    • In large-scale randomized trials and their meta-analyses, beta-adrenergic blockers and angiotensin-converting enzyme inhibitors provide statistically significant and clinically important additive mortality and morbidity benefits in the treatment of heart failure. The CHARM trials were designed to test whether the angiotensin-receptor blocker candesartan would provide statistically significant and clinically important additive mortality and morbidity benefits to patients with heart failure as an alternative or in addition to angiotensin-converting enzyme inhibitors. CHARM demonstrated that an angiotensin-receptor blocker at a proven dose is an effective and safe therapy as an alternative or in addition to angiotensin-converting enzyme inhibitors in patients with heart failure, 55% of whom were receiving beta-adrenergic blockers. These benefits include reductions in cardiovascular mortality rate as well as in hospitalization for heart failure. Such patients have a 50% mortality rate at 5 years, and heart failure is the leading cause of hospitalization for patients 65 years of age and older.
  •  
3.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-3 of 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view